Altria's Best Hope for a Bounce

Tobacco stocks have performed badly in 2018, and even industry leader Altria Group (NYSE:MO) hasn’t been able to avoid the carnage. With the stock down 20% halfway through the year, Altria is dealing with a host of challenges, ranging from increased regulatory attention to alternative products and calls from dramatic reductions in nicotine levels in its existing product lineup.

Altria will likely release its second-quarter financial report about a month from now on July 26. Yet already, shareholders are clamoring for the company to come up with a viable strategy to work past its recent woes and find a new growth path higher. Without a more definitive plan from newly installed CEO Howard Willard to find a clearer growth trajectory, Altria risks remaining under pressure for the rest of 2018.

Stats on Altria Group’s second-quarter earnings

EPS Estimate

$1.00

Change From Year-Ago EPS

18%

Revenue Estimate

$5 billion*

Change From Year-Ago Revenue

(1.2%)

Earnings Beats in Past 4 Quarters

3

Data source: Yahoo! Finance. * Net of excise tax.

What’s ahead for Altria?

Investors haven’t been as confident about Altria’s earnings prospects lately as they were in the past. Over the last three months, investors have scaled back their expectations for the current quarter, although they believe that better performance later in the year could boost full-year earnings projections. The stock, though, has been weighed down, falling almost 9% since late March.

Altria’s first-quarter report started off the year on a mixed note. Revenue in the smokeable products unit, which includes the key Marlboro brand along with other cigarette offerings, was higher by just a fraction of a percent, with Altria’s regular strategy of boosting prices was just barely able to offset greater promotional investment and reduced sales volumes. Cigarette shipments were down more than 4% from year-earlier levels, and Altria saw continued deterioration in its market share, which stayed just above the 50% mark. Altria’s smokeless tobacco unit rebounded from a tough first quarter in 2017, and earnings from the tobacco company’s investment in beer giant Anheuser-Busch also paid off well.

Sign with Altria name and logo on it, outside with a flagpole behind it.

Image source: Altria Group.

One even larger threat emerged from an unexpected corner during the quarter. For a while, Altria and its peers in the industry have looked to potential reduced-risk products like e-cigarettes and heated tobacco units as possibly replacing some of their lost sales from traditional cigarettes. The popularity of alternative products has been on the rise, especially with competitor JUUL Labs and its line of e-cigarettes. Yet when Altria partner Philip Morris International (NYSE:PM) reported its latest quarterly results, they included an unexpected slowdown in growth rates of adoption of its iQOS heated tobacco system. Altria hopes eventually to winapproval from the Food and Drug Administration to sell iQOS in the U.S. through a licensing agreement with Philip Morris, and the possibility that the system might not have as steep and long-lasting a growth curve as previously expected attacked the fundamental underpinnings of the hopes many investors have about Altria’s long-term future.

Looking ahead, one of the most important considerations will be how Howard Willard puts his mark on Altria as new CEO. So far, Willard hasn’t been all that outspoken about his vision, having chosen not to speak either on Altria’s first-quarter conference call or at its annual shareholder meeting in May. However, one of Willard’s first moves was to make some major organization and leadership changes within Altria, establishing two separate divisions to cover core tobacco operations and innovative tobacco products separately. By changing the traditional smokeable and smokeless tobacco segments, Willard recognizes that innovation will be an essential part of Altria’s future survival, and he needs to be able to measure that directly. With Nu Mark to oversee the development of e-cigarettes, oral nicotine products, and similar alternatives, Altria is concentrating its highest-potential projects under longtime smokeless tobacco executive Brian Quigley while leaving its core portfolio under the direct management of Nu Mark president Jody Begley.

Reorganization efforts by themselves won’t solve Altria’s problems, and regulation will remain a key impediment to growth prospects. Altria’s second-quarter earnings aren’t likely to show huge progress, but even incremental gains should be received well if they come with a clearer view of what Willard and his executive team intend to do to make the most of the tobacco giant’s business opportunities. Building confidence in the future is the best thing Altria could do to bounce back from its recent challenges.

Zacks: Analysts Anticipate Bojangles Inc (BOJA) Will Announce Quarterly Sales of $140.38 Million

Equities research analysts expect that Bojangles Inc (NASDAQ:BOJA) will report $140.38 million in sales for the current quarter, according to Zacks. Six analysts have provided estimates for Bojangles’ earnings. The lowest sales estimate is $139.80 million and the highest is $141.18 million. Bojangles reported sales of $134.37 million in the same quarter last year, which would suggest a positive year over year growth rate of 4.5%. The business is scheduled to issue its next earnings results on Thursday, July 26th.

On average, analysts expect that Bojangles will report full-year sales of $559.84 million for the current fiscal year, with estimates ranging from $556.30 million to $565.56 million. For the next financial year, analysts anticipate that the firm will report sales of $567.92 million per share, with estimates ranging from $557.88 million to $588.57 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that cover Bojangles.

Get Bojangles alerts:

Bojangles (NASDAQ:BOJA) last announced its earnings results on Tuesday, May 8th. The restaurant operator reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.02. The business had revenue of $137.49 million during the quarter, compared to the consensus estimate of $134.53 million. Bojangles had a net margin of 12.48% and a return on equity of 11.97%. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.20 earnings per share.

Several research analysts have recently weighed in on the stock. Barclays upped their target price on shares of Bojangles from $13.00 to $14.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 7th. CL King downgraded shares of Bojangles from a “buy” rating to a “neutral” rating in a research note on Tuesday, April 24th. They noted that the move was a valuation call. Zacks Investment Research downgraded shares of Bojangles from a “hold” rating to a “sell” rating in a research note on Tuesday, March 27th. BidaskClub downgraded shares of Bojangles from a “buy” rating to a “hold” rating in a research note on Friday, April 13th. Finally, ValuEngine downgraded shares of Bojangles from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and two have assigned a buy rating to the stock. Bojangles currently has a consensus rating of “Hold” and an average price target of $16.13.

Shares of Bojangles traded up $0.60, hitting $15.10, on Tuesday, Marketbeat reports. The stock had a trading volume of 8,202 shares, compared to its average volume of 193,999. The company has a market capitalization of $529.93 million, a PE ratio of 17.47, a price-to-earnings-growth ratio of 1.53 and a beta of 1.46. The company has a current ratio of 0.65, a quick ratio of 0.57 and a debt-to-equity ratio of 0.49. Bojangles has a 52-week low of $11.35 and a 52-week high of $16.70.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Investors Research Corp acquired a new stake in Bojangles in the fourth quarter valued at $145,000. Yorktown Management & Research Co Inc acquired a new stake in Bojangles in the fourth quarter valued at $289,000. Price Michael F acquired a new stake in Bojangles in the fourth quarter valued at $5,546,000. PEAK6 Investments L.P. acquired a new stake in Bojangles in the fourth quarter valued at $198,000. Finally, BlackRock Inc. raised its holdings in Bojangles by 3.9% in the fourth quarter. BlackRock Inc. now owns 1,103,664 shares of the restaurant operator’s stock valued at $13,023,000 after acquiring an additional 41,583 shares in the last quarter. 92.98% of the stock is currently owned by hedge funds and other institutional investors.

Bojangles Company Profile

Bojangles', Inc develops, operates, and franchises limited service restaurants in the United States. Its restaurants offer made-from-scratch biscuit breakfast sandwiches, hand-breaded bone-in chicken, fixin's, and iced tea. As of December 31, 2017, the company operated 764 system-wide restaurants, including 325 company-operated and 439 franchised restaurants primarily located in the Southeastern United States.

Get a free copy of the Zacks research report on Bojangles (BOJA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bojangles (NASDAQ:BOJA)

Zacks: Brokerages Anticipate Nordson Co. (NDSN) Will Post Quarterly Sales of $549.93 Million

Equities research analysts predict that Nordson Co. (NASDAQ:NDSN) will post $549.93 million in sales for the current quarter, according to Zacks Investment Research. Eight analysts have made estimates for Nordson’s earnings, with estimates ranging from $541.50 million to $555.70 million. Nordson reported sales of $496.14 million during the same quarter last year, which indicates a positive year-over-year growth rate of 10.8%. The business is scheduled to report its next earnings results on Monday, August 20th.

According to Zacks, analysts expect that Nordson will report full year sales of $2.28 billion for the current financial year, with estimates ranging from $2.26 billion to $2.32 billion. For the next fiscal year, analysts anticipate that the company will post sales of $2.38 billion per share, with estimates ranging from $2.32 billion to $2.45 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Nordson.

Get Nordson alerts:

Nordson (NASDAQ:NDSN) last announced its quarterly earnings data on Monday, May 21st. The industrial products company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.43 by $0.13. Nordson had a return on equity of 28.97% and a net margin of 16.63%. The business had revenue of $553.70 million during the quarter, compared to analyst estimates of $551.98 million. During the same period in the prior year, the company earned $1.35 earnings per share. Nordson’s revenue was up 11.6% compared to the same quarter last year.

NDSN has been the subject of a number of analyst reports. Wells Fargo & Co set a $135.00 price target on Nordson and gave the stock a “hold” rating in a report on Wednesday, May 23rd. Zacks Investment Research raised Nordson from a “hold” rating to a “buy” rating and set a $148.00 price target for the company in a report on Wednesday, May 16th. BidaskClub lowered Nordson from a “buy” rating to a “hold” rating in a report on Wednesday, May 2nd. B. Riley cut their price target on Nordson from $175.00 to $165.00 and set a “buy” rating for the company in a report on Wednesday, May 23rd. Finally, ValuEngine lowered Nordson from a “buy” rating to a “hold” rating in a report on Friday, April 27th. Nine analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $153.60.

Hedge funds have recently modified their holdings of the stock. Advisory Services Network LLC raised its position in shares of Nordson by 972.7% in the fourth quarter. Advisory Services Network LLC now owns 1,062 shares of the industrial products company’s stock worth $155,000 after buying an additional 963 shares in the last quarter. CI Global Investments Inc. raised its position in shares of Nordson by 1,721.4% in the first quarter. CI Global Investments Inc. now owns 1,275 shares of the industrial products company’s stock worth $174,000 after buying an additional 1,205 shares in the last quarter. Sapphire Star Partners LP purchased a new stake in shares of Nordson in the fourth quarter worth $212,000. Sequoia Financial Advisors LLC purchased a new stake in shares of Nordson in the fourth quarter worth $213,000. Finally, MML Investors Services LLC purchased a new stake in shares of Nordson in the fourth quarter worth $214,000. Institutional investors own 66.24% of the company’s stock.

Nordson stock opened at $130.49 on Friday. Nordson has a one year low of $107.16 and a one year high of $151.84. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.84 and a quick ratio of 1.31. The firm has a market capitalization of $7.58 billion, a PE ratio of 24.30, a P/E/G ratio of 1.66 and a beta of 1.27.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 12th. Investors of record on Tuesday, May 29th were given a $0.30 dividend. The ex-dividend date was Friday, May 25th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 0.92%. Nordson’s dividend payout ratio (DPR) is presently 22.35%.

About Nordson

Nordson Corporation engineers, manufactures, and markets products and systems to dispense, apply, and control adhesives, coatings, polymers, sealants, biomaterials, and other fluids. Its Adhesive Dispensing Systems segment provides dispensing, coating, and laminating systems for adhesives, lotions, liquids, and fibers to disposable products and roll goods; and product assembly dispensing, coating, and laminating systems for use in paper and paperboard converting applications, as well as for the manufacture of roll goods.

Get a free copy of the Zacks research report on Nordson (NDSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nordson (NASDAQ:NDSN)

Theresa May Coin (MAY) Price Down 44.3% This Week

Theresa May Coin (CURRENCY:MAY) traded down 17.7% against the dollar during the 24 hour period ending at 0:00 AM ET on June 23rd. In the last seven days, Theresa May Coin has traded 44.3% lower against the dollar. One Theresa May Coin coin can currently be bought for about $0.0016 or 0.00000026 BTC on cryptocurrency exchanges including YoBit and CoinExchange. Theresa May Coin has a total market cap of $78,433.00 and $384.00 worth of Theresa May Coin was traded on exchanges in the last 24 hours.

Here is how other cryptocurrencies have performed in the last 24 hours:

Get Theresa May Coin alerts:

Emercoin (EMC) traded down 2.3% against the dollar and now trades at $2.51 or 0.00041190 BTC. BitcoinDark (BTCD) traded 6.5% lower against the dollar and now trades at $46.63 or 0.00764208 BTC. Experience Points (XP) traded 14.2% higher against the dollar and now trades at $0.0001 or 0.00000001 BTC. Sprouts (SPRTS) traded down 3.3% against the dollar and now trades at $0.0000 or 0.00000000 BTC. Internet of People (IOP) traded down 1.1% against the dollar and now trades at $0.79 or 0.00013028 BTC. Universal Currency (UNIT) traded down 5.1% against the dollar and now trades at $0.18 or 0.00003004 BTC. Neutron (NTRN) traded 3.2% higher against the dollar and now trades at $0.0705 or 0.00001156 BTC. Breakout (BRK) traded down 2.2% against the dollar and now trades at $0.10 or 0.00001664 BTC. BitTokens (BXT) traded 0.2% higher against the dollar and now trades at $0.53 or 0.00007883 BTC. ParkByte (PKB) traded flat against the dollar and now trades at $0.0233 or 0.00000382 BTC.

Theresa May Coin Profile

Theresa May Coin (MAY) is a PoW/PoS coin that uses the SHA-256 hashing algorithm. It was first traded on April 19th, 2017. Theresa May Coin’s total supply is 49,002,000 coins. Theresa May Coin’s official Twitter account is @theresamaycoin. Theresa May Coin’s official website is www.theresamaycoin.com.

Buying and Selling Theresa May Coin

Theresa May Coin can be purchased on these cryptocurrency exchanges: CoinExchange and YoBit. It is usually not possible to buy alternative cryptocurrencies such as Theresa May Coin directly using US dollars. Investors seeking to acquire Theresa May Coin should first buy Bitcoin or Ethereum using an exchange that deals in US dollars such as Gemini, Changelly or Coinbase. Investors can then use their newly-acquired Bitcoin or Ethereum to buy Theresa May Coin using one of the exchanges listed above.

new TradingView.widget({ “height”: 400, “width”: 650, “symbol”: “MAYUSD”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Vital Therapies Inc (VTL) Expected to Announce Earnings of -$0.33 Per Share

Analysts predict that Vital Therapies Inc (NASDAQ:VTL) will announce ($0.33) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Vital Therapies’ earnings, with estimates ranging from ($0.36) to ($0.30). Vital Therapies posted earnings per share of ($0.29) in the same quarter last year, which would indicate a negative year-over-year growth rate of 13.8%. The firm is expected to announce its next earnings report on Thursday, August 2nd.

On average, analysts expect that Vital Therapies will report full year earnings of ($1.23) per share for the current fiscal year, with EPS estimates ranging from ($1.32) to ($1.13). For the next financial year, analysts forecast that the business will report earnings of ($1.30) per share, with EPS estimates ranging from ($1.43) to ($1.17). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Vital Therapies.

Get Vital Therapies alerts:

Vital Therapies (NASDAQ:VTL) last announced its quarterly earnings results on Tuesday, May 8th. The company reported ($0.34) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.34).

Several equities research analysts recently commented on the stock. BidaskClub raised shares of Vital Therapies from a “sell” rating to a “hold” rating in a research report on Saturday, May 19th. ValuEngine raised shares of Vital Therapies from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Zacks Investment Research cut shares of Vital Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, March 17th. Finally, BTIG Research reaffirmed a “hold” rating on shares of Vital Therapies in a research report on Monday, May 28th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The stock currently has a consensus rating of “Hold”.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Citigroup Inc. increased its stake in Vital Therapies by 1,093.5% in the 1st quarter. Citigroup Inc. now owns 15,909 shares of the company’s stock valued at $108,000 after buying an additional 14,576 shares during the last quarter. Bank of Montreal Can acquired a new stake in Vital Therapies in the 4th quarter valued at $118,000. Dowling & Yahnke LLC acquired a new stake in Vital Therapies in the 1st quarter valued at $136,000. Two Sigma Investments LP acquired a new stake in Vital Therapies in the 4th quarter valued at $179,000. Finally, Annex Advisory Services LLC acquired a new stake in Vital Therapies in the 1st quarter valued at $190,000. 28.15% of the stock is currently owned by institutional investors and hedge funds.

VTL traded up $0.70 during trading on Monday, hitting $6.50. The company had a trading volume of 2,918,391 shares, compared to its average volume of 286,035. The stock has a market capitalization of $245.74 million, a P/E ratio of -4.96 and a beta of 4.23. Vital Therapies has a one year low of $2.42 and a one year high of $7.30.

About Vital Therapies

Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.

Get a free copy of the Zacks research report on Vital Therapies (VTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vital Therapies (NASDAQ:VTL)

Banks May Be Using Lehman-Style Trick to Disguise Debt

LISTEN TO ARTICLE 2:35 SHARE THIS ARTICLE Facebook Twitter LinkedIn Email

Banks may be disguising their borrowings in a way similar to that used by Lehman Brothers Holdings Inc., with debt ratios falling within limits imposed by regulators just four times a year.

Lenders use repurchase agreements — known as repos — to massage down their assets as reporting dates approach, typically as quarters end, the Bank for International Settlements said in its Annual Economic Report. The practice boosts leverage ratios — the ratio between capital and so-called leverage exposures — allowing banks to report them as being in line with regulatory requirements, it said.

“The data indicate that window-dressing in repo markets is material,” BIS analysts said in the report. “Data from U.S. money market mutual funds point to pronounced cyclical patterns in banks’ U.S. dollar repo borrowing, especially for jurisdictions with leverage ratio reporting based on quarter-end figures.”

The practice “reduces the prudential usefulness of the leverage ratio, which may end up being met only four times a year,” said the Basel, Switzerland-based BIS, which is known as the central bank for central banks.

Lehman used repos to disguise its borrowings before it imploded in 2008 in the biggest-ever U.S. bankruptcy. The collapse prompted regulators to close an accounting loophole the firm had wriggled through to mask its debts and to introduce a leverage ratio globally. The Basel Committee on Banking Supervision recommends a minimum 3 percent ratio is used.

Repo Game

As well as negative effects on financial stability, using repos to game the requirement hinders access to the market for those who need it and obstructs monetary policy implementation, the BIS said.

In a repo, banks borrow short term against some of their assets with a promise to repurchase the collateral. The cash raised can then be lent out in a reverse repo and the collateral obtained used to back further borrowing. Closing the reverse repo at quarter-end raises cash that can be used to unwind the repo, shrinking the balance sheet and reducing leverage.

Banks’ ability to engage in this kind of window-dressing depends on the jurisdiction they are in, the BIS said. That’s because while countries including the U.S. and U.K. require lenders to report their leverage ratios based on daily averages over the period, others including France, Germany and Switzerland use end-period reporting.

Since early 2015, when banks began reporting leverage ratios, the size of the swings in the volume of repo transactions carried out by euro-area banks has been rising, according to the BIS. Contractions in the repo market have soared to more than $145 billion at the end of last year from about $35 billion over the period, the BIS said.

A Simple Guide to What Social Security Pays

Social Security provides benefits to a wide range of Americans, including both workers and their family members. Yet it can be almost impossible to keep track of exactly how much money every Social Security recipient is entitled to receive. Not only is the formula for calculating benefits complicated, but the percentages of that calculated amount that various recipients can get differ greatly from person to person.

To find out exactly what you’ll get from Social Security, your Social Security statement is the best place to start. But to help give you a starting point and to understand what various family members can receive as well, this simple guide will get you moving in the right direction.

Two Social Security cards on top of a $100 bill.

Image source: Getty Images.

The starting point

For all benefits, the place where the Social Security Administration first starts is your work history. For determining retirement benefits, the SSA looks at the 35 top-earning years in your career adjusted for inflation. It then figures the average indexed monthly earnings from work record, and plugs the result into a formula that comes up with what’s known as the primary insurance amount.

The primary insurance amount determines what you’d receive in monthly Social Security retirement benefits if you start receiving them at your full retirement age. If you claim earlier or later than that date, then you’ll get less or more in your monthly checks.

Disability benefits are calculated in a similar way, except that the SSA doesn’t require a 35-year work record. Instead, your average earnings over a shorter period of time that better reflects your age will determine the primary insurance amount for disability purposes.

The percentages every family member needs to know

Eligible family members can receive benefits from Social Security based on a worker’s earnings history, and that’s where things can get extremely complicated. Different percentages apply to family benefits depending on whether the worker is still alive or has passed away.

For family benefits while the worker is still alive, family members can receive the following percentage of the worker’s benefit:

Spousal benefits at full retirement age are 50% of the worker’s primary insurance amount. Spousal benefits taken prior to full retirement age are reduced and can be as little as 32.5% of the worker’s benefit. Spousal benefits are available at any age if the spouse is caring for a child younger than 16. Children under 18 or in high school and no older than 19 get a 50% benefit.

If the worker has died, then the following survivor benefits are available, as a percentage of the deceased worker’s benefit:

The surviving spouse gets 100% of the deceased worker’s benefit if the surviving spouse claims at full retirement age or later. Surviving spouses claiming early can get reduced benefits of 71.5% or higher, depending on age. Surviving spouses who are caring for children younger than 16 get 75%. Children under 18 or who are in high school and no older than 19 get 75%. The worker’s parents can receive 75% to 82.5% of the worker’s benefit if they were dependents of the worker. The lower amount applies when both parents are eligible survivors, and each one gets the 75% amount.

One last caveat

Finally, be aware that there’s a maximum amount that Social Security will pay out based on any one person’s work history. That amount is typically between 150% to 180% of the worker’s benefit amount. As a result, large families will often see their individual benefit percentages come in much less than those listed above.

Nevertheless, knowing what Social Security will provide is valuable information for workers and their families to have. That way, you can make contingency plans for a number of scenarios and have the certainty that there won’t be any surprises in the future.

Top Stocks To Invest In 2019

&l;p&g;&l;img class=&q;dam-image ap size-large wp-image-34d89e57f7424200961aa0a929830fd6&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/34d89e57f7424200961aa0a929830fd6/960×0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; Senate Minority Leader Sen. Chuck Schumer of N.Y., attends a news conference on 401(k) retirement savings, Tuesday, Oct. 31, 2017, on Capitol Hill in Washington. (AP Photo/Jacquelyn Martin)

Preparing for retirement is incredibly important for those of us wanting to live a comfortable life. Automatic enrollment in retirement plans has been the behavioral scientist&a;rsquo;s dream come true. It&a;rsquo;s been shown to increase participation in retirement plans and has boosted savings rates among employees around the globe. Now roughly 52% of all 401(k) plans use automatic enrollment to boost retirement saving &a;ndash; great news for financial advisors and retirement counselors. Unfortunately, however, the large uptick in plan balances are now being found to be financed by increasingly larger amounts of debt, &l;a href=&q;https://scholar.harvard.edu/files/laibson/files/total_savings_impact_2017_12_06.pdf&q; target=&q;_blank&q;&g;according to new research&l;/a&g; from scholars at Harvard, Yale and the United States Military Academy.

Top Stocks To Invest In 2019: Companhia Brasileira de Distribuicao(CBD)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    TransEnterix, Inc. (NYSE: TRXC) rose 28.8 percent to $4.03 in pre-market trading after the company disclosed that it has received the FDA clearance for expanded indications for its Senhance Surgical System.
    Global Eagle Entertainment Inc. (NASDAQ: ENT) rose 15.6 percent to $2.30 in pre-market trading.
    Companhia Brasileira de Distribuição (NYSE: CBD) rose 13.2 percent to $24.20 in pre-market trading.
    ZTO Express (Cayman) Inc. (NYSE: ZTO) rose 12.2 percent to $21.65 in pre-market trading. Alibaba and Cainiao agreed to make strategic investment in ZTO Express of $1.38 billion.
    DHI Group, Inc. (NYSE: DHX) rose 10.8 percent to $2.05 in pre-market trading.
    Momo Inc. (NASDAQ: MOMO) shares rose 9.6 percent to $42.68 in pre-market trading after the company reported better-than-expected results for its first quarter and issued strong sales forecast for the second quarter.
    Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares rose 9.1 percent to $6.00 in pre-market trading.
    Universal Display Corporation (NASDAQ: OLED) rose 8.4 percent to $108.00 in pre-market trading.
    Jupai Holdings Limited (NYSE: JP) shares rose 7 percent to $24.50 in pre-market trading after reporting Q1 results.
    Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) rose 5.9 percent to $10.61 in pre-market trading.
    Frontline Ltd. (NYSE: FRO) rose 5.9 percent to $5.04 in pre-market trading.
    Evogene Ltd. (NASDAQ: EVGN) rose 5.5 percent to $3.27 in pre-market trading after reporting Q1 results.
    Sears Holdings Corporation (NASDAQ: SHLD) rose 5.5 percent to $3.68 in pre-market trading after gaining 5.44 percent on Friday.
    Kitov Pharma Ltd (NASDAQ: KTOV) shares rose 5.4 percent to $2.16 in pre-market trading.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Logan Wallace]

    Companhia Brasileira de Distribuicao (NYSE: CBD) and Alimentation Couche-Tard Inc Class B (OTCMKTS:ANCUF) are both retail/wholesale companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Top Stocks To Invest In 2019: Saul Centers, Inc.(BFS)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Teachers Insurance & Annuity Association of America purchased a new position in shares of Saul Centers, Inc. (NYSE:BFS) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 13,437 shares of the real estate investment trust’s stock, valued at approximately $685,000. Teachers Insurance & Annuity Association of America owned approximately 0.06% of Saul Centers at the end of the most recent quarter.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Saul Centers (BFS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Shares of Saul Centers, Inc. (NYSE:BFS) have been assigned a consensus recommendation of “Hold” from the seven analysts that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $54.50.

Top Stocks To Invest In 2019: Unilever NV(UN)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Stepan (NYSE: SCL) and Unilever (NYSE:UN) are both basic materials companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

  • [By Isaac Pino, CPA]

    If you’re an investor in consumer goods giant Unilever (NYSE:UN), odds are you followed the takeover bid from Kraft Heinz(NASDAQ: KHC) closely in 2017. Ultimately, it fell through, with Unilever’s management rebutting that it was better off on its own. There was some mustard left on the face of Kraft Heinz, but major shareholder Warren Buffett claimed there was potentially a misunderstanding of the nature of the offer. It was not intended to be a hostile takeover, he said, but it could have been perceived that way by Unilever.

  • [By Joseph Griffin]

    Unilever (NYSE:UN) has earned an average recommendation of “Hold” from the nine research firms that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, three have given a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company.

  • [By Ethan Ryder]

    ETRADE Capital Management LLC increased its holdings in Unilever (NYSE:UN) by 20.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,787 shares of the company’s stock after buying an additional 4,767 shares during the period. ETRADE Capital Management LLC’s holdings in Unilever were worth $1,567,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By ]

    A company like Procter & Gamble, Unilever NV (UN) , CVS Health Corp. (CVS) or Walgreens Boots Alliance Inc. (WBA) might be interested in the Pfizer business, said Anthony Chambers, a director in the life sciences practice of consulting firm West Monroe Partners.

  • [By Logan Wallace]

    Unilever NV (NYSE:UN)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $57.01, but opened at $55.62. Unilever shares last traded at $54.04, with a volume of 2279393 shares.

Diffusion Pharmaceuticals (DFFN) Given Media Impact Rating of 0.09

News coverage about Diffusion Pharmaceuticals (NASDAQ:DFFN) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Diffusion Pharmaceuticals earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave news headlines about the company an impact score of 44.7897373236978 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Shares of Diffusion Pharmaceuticals traded down $0.03, hitting $0.52, during midday trading on Friday, Marketbeat reports. 174,998 shares of the stock were exchanged, compared to its average volume of 250,019. The company has a market capitalization of $27.28 million, a PE ratio of -0.45 and a beta of -1.06. Diffusion Pharmaceuticals has a twelve month low of $0.42 and a twelve month high of $3.04.

Get Diffusion Pharmaceuticals alerts:

Diffusion Pharmaceuticals (NASDAQ:DFFN) last released its quarterly earnings results on Thursday, May 10th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.22). equities analysts forecast that Diffusion Pharmaceuticals will post -0.44 EPS for the current year.

Several research analysts have recently issued reports on the company. ValuEngine raised Diffusion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. HC Wainwright set a $1.00 price target on Diffusion Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, April 16th.

Diffusion Pharmaceuticals Company Profile

Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke.

Insider Buying and Selling by Quarter for Diffusion Pharmaceuticals (NASDAQ:DFFN)

5 Biggest Blockbuster Diabetes Drugs of the Future

Forty-six billion dollars. That’s a big number — and it’s how much was made worldwide from selling diabetes drugs in 2017.

You can count on that total growing over the next several years, as more people are being diagnosed with diabetes at alarming rates. And now, more powerful drugs are being developed. All of this makes the diabetes market an intriguing opportunity for investors.

Market research firm EvaluatePharma recently ranked what it projects will be the top diabetes drugs of 2024. Novo Nordisk’s (NYSE:NVO) products dominate the list, although Eli Lilly (NYSE:LLY) and privately held Boehringer Ingelheim placed highly, as well. Here are the top five biggest blockbuster diabetes drugs of the future, according to EvaluatePharma.

Physician with stethoscope writing the word "diabetes" on glass window

Image source: Getty Images.

1. Trulicity

Eli Lilly’s Trulicity is projected to be the No. 1 top-selling diabetes drug in the world by 2024. EvaluatePharma thinks the drug will rake in annual sales of $4.6 billion and claim a market share of 7.8%.

Trulicity is a glucagon-like peptide 1 (GLP-1) receptor agonist that helps the body release insulin more effectively. The drug won Food and Drug Administration (FDA) approval in 2014 for treating type 2 diabetes. Sales for Trulicity totaled more than $2 billion last year, with a global market share of 4.4%.

2. Ozempic

Lilly will need to watch out: Novo Nordisk will be breathing down its neck with its own GLP-1 receptor agonist, Ozempic. EvaluatePharma expects Ozempicwill make $4.4 billion in sales in 2024, giving Novo’s drug a 7.4% market share.

Ozempicalso ranked second on another EvaluatePharma list — the biggest new drug launches of 2018. Novo Nordisk won FDA approval of the drug in treating type 2 diabetes in December 2017, but the full launch of Ozempicbegan this year. The drug got off to a decent start in Q1, with Novo reporting sales for Ozempic of69 million Danish krone ($11 million as of May 7, 2018).

3. Jardiance

BoehringerIngelheim and Lilly co-market Jardiance, which is projected to be the No. 3 best-selling diabetes drug in the world in 2024. The drug is expected to generate sales that year of $3.5 billion and capture 5.9% of the worldwide diabetes drug market.

Jardiance is the most successful of several sodiumglucose co-transport (SGLT) 2 inhibitors. It won FDA approval in 2014 for treating type 2 diabetes and secured another approval in 2016 for reducing cardiovascular death in adults with type 2 diabetes. The drug made a little over $1.1 billion last year, with Lilly’s portion of sales totaling close to $448 million.

4. Tresiba

Novo Nordisk’s second product in the top five is insulin analog Tresiba. EvaluatePharma thinks that Tresiba will generate revenue of nearly $3.4 billion in 2024, with a market share of 5.7%.

Tresiba first won FDA approval in 2015 for use by adults with diabetes and gained an additional approval the following year for treatment of children and adolescents with diabetes. Novo Nordisk notched sales of $1.1 billion for the insulin product in 2017 and claimed a market share of 2.4%.

5. NovoRapid

Only one of the top five best-selling diabetes drugs of the future is expected to experience a decrease in sales. Novo Nordisk’s insulin analog NovoRapid likely will see its market share slip from 6.6% in 2017 to 4.3% in 2024. However, the product should still bring in more than $2.5 billion.

After years on the market, key patents for NovoRapid expired in 2014. Novo Nordisk recorded sales of around $3 billion for the product last year. While sales will slip, the decline will be a relatively mild and gradual one.

Investing opportunities?

With these diabetes drugs on track to rack up billions of dollars in sales in the coming years, are Lilly and Novo Nordisk great stocks to buy right now? Maybe.

If you’re looking for income, either of these stocks will probably look pretty good. Lilly’s dividend yield stands at 2.6%, while Novo’s yield is nearly 2.9%.

The growth scenario is murkier. Both companies have promising new drugs and pipelines, but both also are weighed down by headwinds for older drugs.My view is thatNovo Nordisk could be in better shape over the long run, especially if clinical studies for an oral version of Ozempic are successful.